A note on sample size determination for bioequivalence studies with higher-order crossover designs

被引:14
作者
Chen, KW [1 ]
Chow, SC
Li, G
机构
[1] Pasteur Merieux Connaught, Dept Med Affairs, Swiftwater, PA 18370 USA
[2] Covance Clin & Periapproval Serv Inc, Biostat & Data Management, Princeton, NJ 08540 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1997年 / 25卷 / 06期
关键词
sample size; higher order crossover design; power; bioequivalence;
D O I
10.1023/A:1025738019069
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Similar to Liu and Chow, approximate formulas for sample size determination are derived based on Schuirmann's two one-sided tests procedure for bioequivalence studies for the additive and the multiplicative models under various higher order crossover designs for comparing two formulations of a drug product. The higher order crossover designs under study include Balaam's design, the two-sequence dual design, and two four-period designs (with two and four sequences), which are commonly used for assessment of bioequivalence between formulations. The derived formulas are simple enough to be carried out with a pocket calculator. The number of subjects required for each of the four higher order designs are tabulated for selected powers and various parameter values.
引用
收藏
页码:753 / 765
页数:13
相关论文
共 8 条
[1]  
Chow S C, 1992, J Biopharm Stat, V2, P239, DOI 10.1080/10543409208835042
[2]  
Chow S.C., 1995, DRUG INF J, V29, P795
[3]  
DILETTI E, 1992, INT J CLIN PHARM TH, V30, P287
[4]  
DILETTI E, 1991, INT J CLIN PHARM TH, V29, P1
[5]  
HAUSCHKE D, 1992, J PHARMACOKINETICS B, V20, P559
[6]   SAMPLE-SIZE DETERMINATION FOR THE 2 ONE-SIDED TESTS PROCEDURE IN BIOEQUIVALENCE [J].
LIU, JP ;
CHOW, SC .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1992, 20 (01) :101-104
[7]   A COMPARISON OF THE 2 ONE-SIDED TESTS PROCEDURE AND THE POWER APPROACH FOR ASSESSING THE EQUIVALENCE OF AVERAGE BIOAVAILABILITY [J].
SCHUIRMANN, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (06) :657-680
[8]  
STEINIJANS VW, 1992, INT J CLIN PHARM TH, V30, P571